Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 73, Issue 2, 1997, Pages 149-152

  Başbuǧ, Mustafa ^a,b   Aygen, Ercan ^a   Tayyar, Mehmet ^a   Muhtaroǧlu, Sebahattin ^a   Demir, Ibrahim ^a   Ökten, Süheyl ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Cardiovascular disease; Conjugated estrogen; Sex hormone binding globulin; Transdermal estradiol

Indexed keywords

ESTRADIOL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; MENOPAUSAL SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0342618775     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(97)02706-1     Document Type: Article

References (20)

1. Geola FL, Frumar AM, Tatary IV, Hersman JM, Eggena P, Sambhi MP, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980; 51: 620-625.
2. Judd HL: Transdermal estradiol. J Reprod Med 1994; 39: 343-352.
3. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, et al. Biologic effects of transdermal estradiol. New Engl J Med 1986; 314: 1615-1620.
4. Padwick ML, Endacott J, Whitehead MI. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 1985; 152: 1085-1091.
5. Laufer LR, DeFazio JL, Lu JKH, Meldrum DR, Eggena P, Sambhi MP, et al. Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol 1983; 146: 533-538.
6. Hass S, Walsh B, Evans S, Krache M, Ravnikar V, Schiff I. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988; 71: 671-676.
7. Slowinska-Srzednicka J, Zgliczynski S, Jeske W, Stopinska-Gluszak U, Srzednicki M, Brzezinska A, et al. Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J Endocrinol Invest 1992; 15: 533-538.
8. Pang SC, Greendale GA, Cedars MI, Gambone JC, Lozano K, Eggena P, et al. Long -term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril 1993; 59: 76-82.
9. Castello-Branco C, Martinez de Osaba MJ, Fortuny A, Iglesias X, Gonzalez-Merlo J. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. J Reprod Med 1995; 40: 556-560.
10. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144: 511-518.
11. Miller-Bass K, Adashi EY. Current status and future prospects of transdermal estrogen replacement therapy. Fertil Steril 1990; 53: 961-974.
12. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 β-estradiol: Comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-1106.
13. Refn H, Kjaer A, Lebech AM, Borggaard B, Schierup L, Bremmelgaard A. Metabolic changes during treatment with two different progestogens. Am J Obstet Gynecol 1990; 163: 374-377.
14. Campagnoli C, Biglia N, Lanza MG, Lesca L, Peris C, Sismondi P. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in post-menopausal women. Preliminary report. Maturitas 1994; 19: 25-31.
15. Campagnoli C, Biglia N, Belforte P, Botta N, Pedrini E, Sismondi P. Postmenopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables. Eur J Gynaecol Oncol 1992; 13: 139-154.
16. Pike MC, Bernstein L, Spider DV. The relationship of exogenous hormones to breast cancer risk. In: Niederhuber JE, ed. Current therapy in oncology. St. Louis: BC Decker, 1993; 292-303.
17. Bruning PF, Bonfer JMG. Free fatty acid concentrations correlated with the available fraction of estradiol in the human plasma. Cancer Res 1986; 46: 2606-2610.
18. Pansini F, Bonaccorsi G, Genovesi F, Folegatti MR, Bagni B, Bergamini CM, Mollica G. Influence of estrogens on serum free fatty acid levels in women. J Clin Endocrinol Metab 1990; 71: 1387-1389.
19. Murai JT, Mendel CM, Siiteri PK. Free fatty acids do not influence the concentration of free steroid hormones in serum under physiological conditions. J Clin Endocrinol Metab 1991; 72: 137-139.
20. Pugeat M, Moulin P, Cousin P, Fimbel S, Nicolas MH, Crave JC, Lejeune H. Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. J Steroid Biochem Mol Biol 1995; 53: 567-572.